Centene (CNC) Projected to Post Earnings on Tuesday

Centene (NYSE:CNC) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, February 4th. Analysts expect the company to announce earnings of $0.44 per share and revenue of $38,782,600.00 billion for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Centene Trading Up 2.0 %

NYSE CNC opened at $65.88 on Tuesday. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64. The business has a fifty day simple moving average of $60.63 and a 200 day simple moving average of $67.25. Centene has a 12 month low of $55.03 and a 12 month high of $81.42. The firm has a market capitalization of $33.26 billion, a P/E ratio of 11.44, a PEG ratio of 0.85 and a beta of 0.45.

Insider Transactions at Centene

In other Centene news, Director Thomas Greco purchased 17,000 shares of the firm’s stock in a transaction on Wednesday, December 18th. The shares were purchased at an average cost of $59.75 per share, with a total value of $1,015,750.00. Following the completion of the purchase, the director now owns 19,309 shares of the company’s stock, valued at $1,153,712.75. The trade was a 736.25 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew Lynn Asher bought 17,200 shares of Centene stock in a transaction that occurred on Wednesday, November 13th. The shares were acquired at an average cost of $58.14 per share, for a total transaction of $1,000,008.00. Following the acquisition, the chief financial officer now owns 486,847 shares in the company, valued at $28,305,284.58. The trade was a 3.66 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 45,010 shares of company stock valued at $2,660,276. Insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Jefferies Financial Group lowered shares of Centene from a “hold” rating to an “underperform” rating and decreased their price objective for the company from $68.00 to $52.00 in a research note on Tuesday, December 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $90.00 target price on shares of Centene in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $75.00 price objective (down previously from $80.00) on shares of Centene in a report on Tuesday, December 17th. Sanford C. Bernstein cut their target price on shares of Centene from $96.00 to $88.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. Finally, UBS Group raised shares of Centene from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $79.00 to $80.00 in a report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $80.92.

Centene Company Profile

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.